Ascentage Pharma Group International (NASDAQ:AAPG) Given “Buy” Rating at BTIG Research

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report)‘s stock had its “buy” rating restated by BTIG Research in a research report issued on Tuesday, Benzinga reports. They presently have a $48.00 target price on the stock. BTIG Research‘s price objective indicates a potential upside of 261.17% from the company’s previous close.

AAPG has been the subject of several other reports. Citigroup assumed coverage on Ascentage Pharma Group International in a research note on Wednesday, October 14th. They set a “buy” rating and a $46.00 price objective for the company. William Blair initiated coverage on shares of Ascentage Pharma Group International in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Citizens Jmp began coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 target price on the stock. Finally, JPMorgan Chase & Co. lowered their target price on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a report on Thursday, October 8th. Two research analysts have rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $43.44.

Get Our Latest Stock Report on AAPG

Ascentage Pharma Group International Stock Down 9.1%

Shares of AAPG opened at $13.29 on Tuesday. Ascentage Pharma Group International has a 1 year low of $13.25 and a 1 year high of $33.09. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. The stock has a 50 day simple moving average of $15.28 and a 200-day simple moving average of $19.55.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The company had revenue of $22.24 million during the quarter. As a group, equities research analysts expect that Ascentage Pharma Group International will post -2.43 earnings per share for the current fiscal year.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Featured Stories

Analyst Recommendations for Ascentage Pharma Group International (NASDAQ:AAPG)

Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.